by George Ciuciureanu | Mar 10, 2025 | Health, News
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and...
by George Ciuciureanu | Jan 31, 2025 | Health, News
Vancouver, Canada – January 28, 2025 – The Spondylitis Association of America (SAA) invited Dr. Walter Maksymowych to join their latest episode of Spondycast, where he discusses the growing role of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) in the...
by Simran Chahal | Jan 27, 2025 | Health, News
Vancouver, Canada – January 27, 2025 – Delays in diagnosing axial spondyloarthritis (axSpA) have been a persistent challenge, with many patients waiting 7 to 10 years for an accurate diagnosis. These delays can lead to missed opportunities for early treatment and a...
by Simran Chahal | Nov 15, 2024 | Business, Health, News
Augurex Life Sciences partners with Quest Diagnostics to relaunch the 14-3-3η test in the U.S., addressing growing demand for advanced rheumatoid arthritis diagnostics.The partnership expands access to the 14-3-3η test through Quest’s extensive physician network and...
by Simran Chahal | Nov 13, 2024 | Business, Health, News
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis.Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
by Simran Chahal | Oct 21, 2024 | Business, Health, News
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
